Supplementary Material
HNSCC, tumor, QuPath, TILs
ADVERSE EVENTS, TUMOR, PATHOLOGY, CYTOTOXICITY
The details for the assays and image analysis are summarized in the Supplementary Materials and Methods.Click here for additional data file.Supplementary Table 1a. Representativeness of Study Participants SupplementaryTable 1b. Nanostring IO360 panelClick here for additional data file.Supplementary Table 2. Signature scores with significanlty changes pre- and post-Olaparib based treatmentClick here for additional data file.Supplementary Table 3. Genes with significanlty changes pre- and post-Olaparib based treatmentClick here for additional data file.Table 4a. Fold-change values for each signature between Response and No Response based on physical examination, pathology or imagingTable 4b. Fold-change values for significantly differentially expressed genes between Response and No Response based on physical examination, pathology or imagingClick here for additional data file.Supplementary Table 5. Incidence of adverse events by maximum grade in the safety population.Click here for additional data file.Supplementary Figure 1. Differentially expressed genes (Left) and gene signatures (Right) Cisplatin-Olaparib (A, B), Olaparib (C,D) and Durvalumab-Olaparib (E, F) arms in pre- and post-treatment samples. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.Click here for additional data file.Supplementary Figure 2. Differentially expressed signatures in Responders relative to no-Responders. Response is based on physical examination, pathology or imaging. Responders had higher scores in Inflammatory Chemokines and Exhausted CD8 Signatures, as well as PD-1, Cytotoxicity and CD45. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.Click here for additional data file.Supplementary Figure 3. A. No significant differences in stromal TILs were found between pre- and post-treatment samples in all arms. In Arm D TILs were increased post-treatment in most of the samples (5 out of 7). Figures B and C show representative images of TILs in pre- and post-treatment samples respectively from one patient in Arm D, measured by QuPath v0.3.0. Figures show tissues before (left) and after (right) QuPath annotations. Color legend; red, tumor cells; purple, lymphocytes; green, fibroblasts; yellow, other; Cisplatin-Olaparib, C-O; Olaparib, O; Durvalumab-Olaparib, D-OClick here for additional data file.Supplementary Figure 4. Relative fold change (2-ΔΔCq) of PD-L1 in respect to Β2Μ (reference gene) in the CTC fraction for individual samples of HNSCC patients before (blue) and after (orange) therapy.Click here for additional data file.Supplementary Figure 5. Map showing the distribution of mutations per gene per tumor. Light and dark purple, green and orange indicate pre- and post-treatment samples for patients treated with cisplatin and olaparib, olaparib and durvalumab and olaparib only, respectively. Blues correspond to samples before and after second biopsy/surgery for patients who did not receive treatment.Click here for additional data file.Supplementary Figure 6. Posttreatment CD163 (by QIF) increase in three patients with concurrent increase in the CD163 transcripts. Representative images from a patient’s tumor tissue sample showing pre and post treatment (Durvalumab-Olaparib Arm) CD163 expression. Nuclei (blue), Cytokeratin (green), CD163 (yellow) and CSF1R (red).Click here for additional data file.